Furthermore, this study aims to examine the chemotherapeutic efficacy of novel formulations as inhibitors of the Her2/neu pathway and their ability to target the FGFR2/FGF2 axis mechanisms and enhance the apoptotic activity in cancer cells. The gene discussed is FGF2; the disease is cancer.